|
1
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartz M, Roayaie S and Konstadoulakis
M: Strategies for the management of hepatocellular carcinoma. Nat
Clin Pract Oncol. 4:424–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poon RT and Fan ST: Hepatectomy for
hepatocellular carcinoma: Patient selection and postoperative
outcome. Liver Transpl. 10 2 Suppl 1:S39–S45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu MC and Yuan JM: Environmental factors
and risk for hepatocellular carcinoma. Gastroenterology. 127 5
Spuul 1:S72–S78. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park KU, Seo YS, Lee YH, Park J, Hwang I,
Kang KJ, Nam J, Kim SW and Kim JY: Altered microRNA expression
profile in hepatitis B virus-related hepatocellular carcinoma.
Gene. 573:278–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han DH, Choi GH, Kim KS, Choi JS, Park YN,
Kim SU, Park JY, Ahn SH and Han KH: Prognostic significance of the
worst grade in hepatocellular carcinoma with heterogeneous
histologic grades of differentiation. J Gastroenterol Hepatol.
28:1384–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bosch FX, Ribes J, Diaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127:(5 Suppl 1): S5–S16. 2004. View Article : Google Scholar
|
|
10
|
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu
C, Zou L, Li Z, Zhao J and Lin N: MicroRNA-101 suppresses
SOX9-dependent tumorigenicity and promotes favorable prognosis of
human hepatocellular carcinoma. FEBS Lett. 586:4362–4370. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harlan LC, Parsons HM, Wiggins CL, Stevens
JL and Patt YZ: Treatment of hepatocellular carcinoma in the
community: Disparities in standard therapy. Liver Cancer. 4:70–83.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Papaconstantinou I, Karakatsanis A,
Gazouli M, Polymeneas G and Voros D: The role of microRNAs in liver
cancer. Eur J Gastroenterol Hepatol. 24:223–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rottiers V, Najafi-Shoushtari SH, Kristo
F, Gurumurthy S, Zhong L, Li Y, Cohen DE, Gerszten RE, Bardeesy N,
Mostoslavsky R and Näär AM: MicroRNAs in metabolism and metabolic
diseases. Cold Spring Harb Symp Quant Biol. 76:225–233. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z
and Jiang J: miR-214 inhibits cell growth in hepatocellular
carcinoma through suppression of β-catenin. Biochem Biophys Res
Commun. 428:525–531. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao G, Wang T, Huang QK, Pu M, Sun W,
Zhang ZC, Ling R and Tao KS: MicroRNA-548a-5p promotes
proliferation and inhibits apoptosis in hepatocellular carcinoma
cells by targeting Tg737. World J Gastroenterol. 22:5364–5373.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ruan T, He X, Yu J and Hang Z:
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo
signaling and tumorigenesis in hepatocellular carcinoma. Oncol
Lett. 11:2941–2945. 2016.PubMed/NCBI
|
|
23
|
Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y,
Fan S and Liu Y: MicroRNA-187, down-regulated in clear cell renal
cell carcinoma and associated with lower survival, inhibits cell
growth and migration though targeting B7-H3. Biochem Biophys Res
Commun. 438:439–444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang ZS, Zhong M, Bian YH, Mu YF, Qin SL,
Yu MH and Qin J: MicroRNA-187 inhibits tumor growth and invasion by
directly targeting CD276 in colorectal cancer. Oncotarget.
7:44266–44276. 2016.PubMed/NCBI
|
|
25
|
Casanova-Salas I, Masiá E, Armiñán A,
Calatrava A, Mancarella C, Rubio-Briones J, Scotlandi K, Vicent MJ
and López-Guerrero JA: miR-187 targets the androgen-regulated gene
ALDH1A3 in prostate cancer. PLoS One. 10:e01255762015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azad F Mirzadeh, Naeli P, Malakootian M,
Baradaran A, Tavallaei M, Ghanei M and Mowla SJ: Two lung
development-related microRNAs, miR-134 and miR-187, are
differentially expressed in lung tumors. Gene. 577:221–226. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F
and Li D: MicroRNA-187-3p mitigates non-small cell lung cancer
(NSCLC) development through down-regulation of BCL6. Biochem
Biophys Res Commun. 471:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chao A, Lin CY, Lee YS, Tsai CL, Wei PC,
Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al: Regulation of
ovarian cancer progression by microRNA-187 through targeting
disabled homolog-2. Oncogene. 31:764–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lynam-Lennon N, Bibby BA, Mongan AM,
Marignol L, Paxton CN, Geiersbach K, Bronner MP, O'Sullivan J,
Reynolds J and Maher SG: Low miR-187 expression promotes resistance
to chemoradiation therapy in vitro and correlates with treatment
failure in patients with esophageal adenocarcinoma. Mol Med.
22:2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
E C, Li J, Shao D, Zhang D, Pan Y, Chen L
and Zhang X: The insulin-like growth factor-I receptor inhibitor
picropodophyllin-induced selective apoptosis of hepatocellular
carcinoma cell through a caspase-dependent mitochondrial pathway.
Oncol Res. 21:103–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J,
Hu S and Xiao W: Induction of IGF-1R expression by EGR-1
facilitates the growth of prostate cancer cells. Cancer Lett.
317:150–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei YH, Tang HX, Liao YD, Fu SL, Xu LQ,
Chen G, Zhang C, Ju S, Liu ZG, You LK, et al: Effects of
insulin-like growth factor 1 receptor and its inhibitor AG1024 on
the progress of lung cancer. J Huazhong Univ Sci Technolog Med Sci.
35:834–841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gryko M, Kisluk J, Cepowicz D, Zińczuk J,
Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona
A and Kędra B: Expression of insulin-like growth factor receptor
type 1 correlate with lymphatic metastases in human gastric cancer.
Pol J Pathol. 65:135–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie QX, Lin XC, Zhang MF, Han CX and Guo
YH: Expression of IGF-I and IGF-IR in bladder cancer. Ai Zheng.
23:707–709. 2004.(In Chinese). PubMed/NCBI
|
|
35
|
Singh RK, Gaikwad SM, Jinager A, Chaudhury
S, Maheshwari A and Ray P: IGF-1R inhibition potentiates cytotoxic
effects of chemotherapeutic agents in early stages of
chemoresistant ovarian cancer cells. Cancer Lett. 354:254–262.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen HX and Sharon E: IGF-1R as an
anti-cancer target-trials and tribulations. Chin J Cancer.
32:242–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singh I, Amin H, Rah B and Goswami A:
Targeting EGFR and IGF 1R: A promising combination therapy for
metastatic cancer. Front Biosci (Schol Ed). 5:231–246. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yue L, Wang Y, Wang H, Gao H, Liang J, Sui
A, Xiang J, Zhou F, Xu C, Zhao W, et al: Inhibition of
hepatocellular carcinoma cell growth by an anti-insulin-like growth
factor-I receptor monoclonal antibody. Oncol Rep. 28:1453–1460.
2012.PubMed/NCBI
|
|
39
|
Zhang YW, Yan DL, Wang W, Zhao HW, Lu X,
Wu JZ and Zhou JR: Knockdown of insulin-like growth factor I
receptor inhibits the growth and enhances chemo-sensitivity of
liver cancer cells. Curr Cancer Drug Targets. 12:74–84. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yao WF, Liu JW, Sheng GL and Huang DS:
Blockade of IGF-IR exerts anticancer effects in hepatocellular
carcinoma. Mol Med Rep. 4:719–722. 2011.PubMed/NCBI
|
